| Name: |
ATROPINE |
| Classification: |
anticholingergic
- used in the treatment of symptomatic sinus bradycardia (not recommended for bradycardias below AV node such as Type II 2o, or complete AV block)
- antidote for sinus bradycardia induced by drugs or toxic substances
- reduces salivation and excessive secretions of the respiratory tract
|
| Dose: |
- IV Direct:
- 0.5-1mg q3-5min until desired rate achieved
- IM/SC:
- when used as a cholinergic antidote may require larger frequent doses
|
| Administration: |
- slow IV administration may result in paradoxical bradycardia and is not recommended
- may be given via endotracheal tube if IV administration not possible
|
| Adverse Effects: |
- tachycardia
- respiratory depression
- blurred vision
- dilated pupils
- dry mouth
- flushed dry skin
- ileus
- urinary retention
|
| Caution: |
- in myasthenia gravis, glaucoma, paralytic ileus, urinary obstruction
|
| Drug Interactions: |
- atropine + phenothiazines = increased anticholinergic effect
- atropine + quinidine = increased anticholinergic effect
- atropine + procainamide = increased anticholinergic effect
|
| Monitoring Therapy: |
|
| CCTC Protocol: |
- May be administered IV direct by an approved nurse in the CCTC.
- May be administered as 0.5mg IV direct without a physician's order by a certified nurse in the CCTC for symptomatic bradycardia <50beats/min (i.e. hypotension, decreased level of consciousness, ventricular ectopics or myocardial ischemia/pain).
|
Print
Handheld
Contrast
